 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...13141516171819202122232425» |
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed
- | Trial completion: Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission (clinicaltrials.gov) - Feb 19, 2014
P3, N=1929, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: St. Vincent Medical Center - Los Angeles
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||| Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Surgery: Surgery in Treating Children With Neuroblastoma (clinicaltrials.gov) - Feb 18, 2014
P3, N=968, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Completed --> Active, not recruiting
- ||| irinotecan / Generic mfg.
Enrollment change, Metastases: IRS-V: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma (clinicaltrials.gov) - Feb 11, 2014
P2, N=77, Completed, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting N=46 --> 77
- ||||| dactinomycin / Generic mfg., vincristine / Generic mfg.
Enrollment change: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (clinicaltrials.gov) - Feb 11, 2014
P3, N=483, Completed, Sponsor: Children's Oncology Group
N=46 --> 77 N=254 --> 483
- |||| irinotecan / Generic mfg.
Trial completion, Metastases: IRS-V: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma (clinicaltrials.gov) - Feb 11, 2014
P2, N=77, Completed, Sponsor: Children's Oncology Group
N=254 --> 483 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment closed: CML 0206: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 5, 2014
P2, N=69, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Trial completion: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Jan 13, 2014
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Vacc C5 / Bionor
Trial completion: Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=36, Completed, Sponsor: Bionor Immuno AS
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Rintega (rindopepimut) / Celldex
Enrollment change: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jan 8, 2014
P3, N=700, Recruiting, Sponsor: Celldex Therapeutics
Active, not recruiting --> Completed N=440 --> 700
- Leukine (sargramostim) / Partner Therap
Trial completion, Tumor cell, Metastases: Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma (clinicaltrials.gov) - Jan 6, 2014
P2, N=200, Completed, Sponsor: Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian
N=440 --> 700 Recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 5, 2014
P1, N=14, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=18 --> 14
- AE 37 / Generex, Leukine (sargramostim) / Partner Therap, GLSI-100 / Greenwich LifeSci
Enrollment closed: BAMC-C.2007.098: Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Dec 30, 2013
P2, N=600, Active, not recruiting, Sponsor: San Antonio Military Medical Center
N=18 --> 14 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
New P1/2 trial: Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (clinicaltrials.gov) - Dec 22, 2013
P1/2, N=30, Recruiting, Sponsor: COL George Peoples, MD, FACS
- MyVax (autologous immunoglobulin idiotype-KLH conjugate vaccine) / Genitope
Trial completion: Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 16, 2013
P2, N=0, Completed, Sponsor: Genitope Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment change: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Dec 15, 2013
P3, N=1660, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=1150 --> 1660
- Leukine (sargramostim) / Partner Therap, IMA950 / Immatics, University Hospitals of Geneva
Enrollment closed, IO biomarker: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma (clinicaltrials.gov) - Dec 8, 2013
P1, N=25, Active, not recruiting, Sponsor: immatics Biotechnologies GmbH
N=1150 --> 1660 Recruiting --> Active, not recruiting
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Enrollment closed, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Dec 5, 2013
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Sitoiganap (ERC1671) / Epitopoietic Research Corp
Enrollment change: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Dec 2, 2013
P2, N=84, Recruiting, Sponsor: Daniela A. Bota
Recruiting --> Active, not recruiting N=70 --> 84
- Leukine (sargramostim) / Partner Therap
Trial completion: Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 25, 2013
P2, N=30, Completed, Sponsor: The Cleveland Clinic
N=70 --> 84 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection (clinicaltrials.gov) - Nov 25, 2013
P3, N=200, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion: Biological Therapy in Treating Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Nov 25, 2013
P2, N=40, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap
New P3 trial, Surgery, Metastases: SWOG-E4697: Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery (clinicaltrials.gov) - Nov 19, 2013
P3, N=800, Completed, Sponsor: National Cancer Institute (NCI)
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer (clinicaltrials.gov) - Nov 18, 2013
P2, N=74, Completed, Sponsor: Michael Morse, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment change: Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer (clinicaltrials.gov) - Nov 17, 2013
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed N=17 --> 8
- Leukine (sargramostim) / Partner Therap
Enrollment closed: GPAD-2: Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease (clinicaltrials.gov) - Nov 14, 2013
P2, N=180, Active, not recruiting, Sponsor: Emory University
N=17 --> 8 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion: Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer (clinicaltrials.gov) - Oct 31, 2013
P2, N=0, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors (clinicaltrials.gov) - Oct 14, 2013
P1, N=16, Recruiting, Sponsor: Roger Williams Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion: Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Oct 13, 2013
P1, N=32, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial termination: Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) (clinicaltrials.gov) - Oct 7, 2013
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Vaccine sponsor ceased operations.
- Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change: Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) (clinicaltrials.gov) - Oct 7, 2013
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Vaccine sponsor ceased operations. N=40 --> 5
- Leukine (sargramostim) / Partner Therap
Trial initiation date: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - Sep 22, 2013
P1, N=32, Recruiting, Sponsor: Howard Gendelman, MD
N=40 --> 5 Initiation date: Jun 2013 --> Sep 2013
- Leukine (sargramostim) / Partner Therap
Enrollment open: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - Sep 22, 2013
P1, N=32, Recruiting, Sponsor: Howard Gendelman, MD
Initiation date: Jun 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion: Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) - Sep 19, 2013
P2, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
New P2 trial: Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) - Sep 9, 2013
P2, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
- Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Enrollment change: Biological Therapy in Treating Women With Stage IV Breast Cancer (clinicaltrials.gov) - Sep 8, 2013
P1/2, N=6, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed N=33 --> 6
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Metastases: Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (clinicaltrials.gov) - Sep 8, 2013
P1/2, N=20, Active, not recruiting, Sponsor: University of Washington
N=33 --> 6 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Trial completion: Biological Therapy in Treating Women With Stage IV Breast Cancer (clinicaltrials.gov) - Sep 8, 2013
P1/2, N=6, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery, Metastases: Biological Therapy Following Surgery and Chemotherapy in Treating Patients With Stage III or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 4, 2013
P2, N=60, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Trial completion, Metastases: CRUK-TELOVAC-V4: Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 22, 2013
P3, N=1110, Completed, Sponsor: Royal Liverpool University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial initiation date: GM-CSF in Treating Patients With Relapsed Prostate Cancer (clinicaltrials.gov) - Aug 14, 2013
P2, N=17, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Initiation date: Oct 2005 --> Jun 2006
- Leukine (sargramostim) / Partner Therap, Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Enrollment change: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=16, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Oct 2005 --> Jun 2006 N=50 --> 16
- Leukine (sargramostim) / Partner Therap
Trial termination: Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 31, 2013
P1, N=3, Terminated, Sponsor: Dartmouth-Hitchcock Medical Center
N=50 --> 16 Active, not recruiting --> Terminated; Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Leukine (sargramostim) / Partner Therap
Biomarker, New P2 trial, Review, Journal, IO biomarker: Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 24, 2013
P2, N=48, Recruiting, Sponsor: UbiVac
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 22, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Terminated; Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Trial initiation date: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Jul 21, 2013
P2, N=48, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Nov 2010 --> Apr 2011
- | Sitoiganap (ERC1671) / Epitopoietic Research Corp
New P2 trial: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Jul 17, 2013
P2, N=84, Recruiting, Sponsor: Daniela A. Bota
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 2, 2013
P2, N=30, Completed, Sponsor: University of Nebraska
Initiation date: Nov 2010 --> Apr 2011 Active, not recruiting --> Completed